PsychoGenics is at the forefront of preclinical neuropathic pain research, focusing on the development and utilization of specialized models to identify and understand complex mechanisms, propelling your breakthrough therapy to clinic. 

Our expertise in nerve ligation models and chemotherapy-induced neuropathic pain, combined with advanced assessment techniques, allows us to offer valuable insights into neuropathic pain pathophysiology, igniting the discovery of your therapeutic intervention.

Preclinical Neuropathic Pain Models

We employ specialized models, techniques, and assessments to precisely evaluate the clinical significance of your potential breakthrough:

PsychoGenics’ researchers employ well-established nerve ligation models, including spinal (L5/L6) nerve ligation (SNL), chronic constriction injury of the sciatic nerve (CCI), and spared nerve injury (SNI). These models mimic neuropathic pain conditions, enabling us to assess the effectiveness of potential interventions in alleviating pain symptoms.

To assess chemotherapy-induced peripheral neuropathic pain, we utilize agents such as paclitaxel, bortezomib, oxaliplatin, and vincristine. These models enable us to gauge the efficacy of emerging therapies in mitigating chemotherapy-induced neuropathy. 

Advance Your Preclinical Neuropathic Pain Research with Unmatched Scientific Excellence

Through our specialized models and comprehensive assessments, PsychoGenics plays a pivotal role in advancing the comprehension and treatment of neuropathic pain. Partner with us to explore innovative avenues in preclinical neuropathic pain research and accelerate the development of your novel therapy.

Partner with us and transform your program


Get Started